FDA Rejects Roche’s Columvi for Earlier-Line Diffuse Large B-Cell Lymphoma

FDA rejection; Columvi; Roche; Genentech; diffuse large B-cell lymphoma; DLBCL; STARGLO study; second-line treatment; Complete Response Letter; gemcitabine; oxaliplatin; accelerated approval; third-line therapy

Genentech’s Kristin Bittenbender Named BIO Board Chair Amid Industry Challenges

BIO; Genentech; Kristin Bittenbender; board chair; biotech industry; FDA; existential threats; leadership change; biotechnology policy